ACP
ELVN icon

Acuta Capital Partners’s Enliven Therapeutics ELVN Stock Holding History

Acuta Capital Partners’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-265,269
Closed -$5.22M – 29
2025
Q1 		$5.22M Sell
265,269
-2,099
-0.8% -$45.2K 6.05% 5
2024
Q4 		$6.02M Sell
267,368
-29,000
-10% -$752K 6.05% 5
2024
Q3 		$7.57M Sell
296,368
-101,330
-25% -$2.35M 6.13% 5
2024
Q2 		$9.29M Buy
397,698
+1,599
+0.4% +$33.7K 7.83% 2
2024
Q1 		$6.97M Buy
396,099
+272,223
+220% +$4.18M 4.53% 8
2023
Q4 		$1.71M Buy
123,876
+20,276
+20% +$248K 0.97% 28
2023
Q3 		$1.42M Sell
103,600
-900
-0.9% -$15.2K 0.95% 30
2023
Q2 		$2.13M Buy
104,500
+73,521
+237% +$1.49M 1.45% 23
2023
Q1 		$678K Buy
30,979
+19,853
+178% +$404K 0.5% 27
2022
Q4 		$182K Buy
+11,126
New +$178K 0.11% 32

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acuta Capital Partners's ELVN Position: Q2 2025 in Review

Acuta Capital Partners sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 265,269 shares — an estimated $5.22M sold.

Acuta Capital Partners first reported a position in ELVN in Q4 2022 and held it in 10 quarters. The position peaked at $9.29M in Q2 2024. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

  • Acuta Capital Partners reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 265,269 Enliven Therapeutics shares in Q2 2025, an estimated $5.22M.
  • Acuta Capital Partners first reported a position in Enliven Therapeutics in Q4 2022 and held it in 10 quarters.
  • Acuta Capital Partners's Enliven Therapeutics position peaked at $9.29M in Q2 2024.
  • 124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on Acuta Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.